US · Healthcare · Biotechnology
EPS came in at -1.52 against a street estimate of -1.16 — a miss of 31.0%.
Analysts rate Palvella Therapeutics, Inc a strong buy (16 buy, 0 hold, 0 sell out of 16) with an average price target of $228.40.
CONFIDENT PVLA achieved Phase III success in microcystic lymphatic malformations, secured FDA rolling review, and submitted first NDA module. On track for full NDA submission H2 2026 and potential approval H1 2027. $251M cash supports robust commercial launch. Q2 2026 No geographic segments discussed; U.S.-focused strategy only. Analysts probed patient population sizing (confirmed >30K conservatively), DSAP vs. angio timing (both on track), and cVM placebo design (FDA alignment pending). Management emphasized data-driven epi, schedule discipline, and collaborative FDA approach. No surprises. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| Suvretta Capital Management, LLC | 7.88% |
| Jennison Associates LLC | 6.67% |
| BlackRock Inc | 6.37% |
| Frazier Life Sciences Management, L.P. | 6.12% |
| First Light Asset Management, LLC | 5.36% |
| Bvf Inc | 4.67% |
| State Street Corp | 4.53% |
| T. Rowe Price Associates, Inc. | 4.43% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • For the nine months ended September 30, 2026, Palvella reported a net loss of $62.280 million, compared with $29.001 million in th | 2026-11-05 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Cash, cash equivalents and short-term investments were $236.7 million as of September 30, 2026. • Third-quarter net loss was $24. | 2026-11-05 |
| Company announcement · Q4 2026 HEADLINE NUMBERS • FDA accepted Palvella Therapeutics’ New Drug Application (NDA) for QTORIN™ 3.9% rapamycin anhydrous gel. • The FDA granted the ap | 2026-10-28 |
| Quarterly report · Q2 2026 PALVELLA THERAPEUTICS, INC. — 10-Q SUMMARY (Q2 2026) --- HEADLINE NUMBERS • Cash Position: $187.8 million in cash and equivalents + $62.8 million i | 2026-08-04 |
| Results announced · Q3 2026 PALVELLA THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and short-term investments: $250.6 million as of | 2026-08-04 |
| Company announcement · Q3 2026 PALVELLA THERAPEUTICS, INC. – 8-K SUMMARY HEADLINE NUMBERS • Company: Palvella Therapeutics, Inc. (Nasdaq: PVLA) • Report Date: July 14, 2026 • Head | 2026-07-14 |
| Board / officer change · Q2 2026 PALVELLA THERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Board size increased from 7 to 8 members on June 29, 2026 • New director granted o | 2026-06-30 |
| Board / officer change · Q2 2026 PALVELLA THERAPEUTICS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Outstanding common stock as of April 13, 2026 (record date): 14,323,686 shares • S | 2026-06-16 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Split | 1 : 80 effective Apr 23, 2024 | 2024-04-23 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Palvella Therapeutics, Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.